HIV Diagnostic Care

Our HIV diagnostic solutions enable lifesaving decisions to be made that have a powerful impact on people, governments, and society. By bringing care where it’s needed most, vulnerable communities have unprecedented access to treatment – and healthcare professionals have what they need to diagnose, treat, and stop HIV transmission.

Point-of-care testing opens the door to effective care for millions of patients worldwide.

UNAIDS calls for nothing less than the end of the AIDS epidemic by 2030.1 These ambitious goals call for rapidly scaling up diagnosis, treatment, and viral suppression, especially in vulnerable populations. With industry-leading products along the cascade of care, Abbott is uniquely able to partner with you to make sure every goal is achieved.

The results speak for themselves. Since 2010, improved access to testing and treatment has resulted in a 26% decline in AIDS-related deaths globally.2

Abbott is the only company with point-of-care diagnostic solutions that addresses nearly every key population along the entire HIV cascade of care.
Abbott is #1 globally among manufacturers of HIV rapid tests.3

Explore our HIV POC Solutions

Get the leading edge in HIV prevention and diagnosis with these Abbott products.

We’re the global leader in rapid point of care testing for HIV.3 Right now, in more than 120 countries, healthcare professionals are using Abbott HIV tests to identify infections earlier, prevent onward transmissions, and change the trajectory of the AIDS epidemic for the better.

HIV Prevention & Early Infant Diagnosis

Every child deserves a HIV-free beginning.

Elimination of new HIV infections among infants is an important part of ending the HIV epidemic. It starts with reducing mother-to-child transmission of both HIV and syphilis. Access to syphilis/HIV diagnostics and timely treatment can minimize the infection risks faced by the unborn child. For infants that acquire HIV, early infant diagnosis with accurate molecular testing can be the difference between life and death. Find the best solution for your littlest patients.

Alere™ q HIV-1/2 Detect

Molecular. Anytime, anywhere. This simple yet smart assay provides next generation virological HIV-1 and HIV-2 results at the point-of-care within 52 minutes.


Same day test and treatment. This test can identify HIV and syphilis in a single visit – from a single drop of blood.

HIV Screening

On the fast track to ending the HIV epidemic: Active Case Finding.

A crucial step to reaching the UNAIDS goals is to make sure people with HIV can be accurately identified now. Identifying HIV-positive patients now not only facilitates fast and appropriate linkage to care – it helps to prevent further transmission of the disease. Our accessible, scalable POC tests for active case finding are designed to go wherever they’re needed – including remote decentralized settings.

Alere™ HIV Combo

A new standard in HIV screening. This 4th generation test detects more acute infections compared to 2nd and 3rd generation tests.

Determine™ HIV Ultra

A new standard in HIV screening. This 4th generation test detects more acute infections compared to 2nd and 3rd generation tests.

HIV Treatment and Clinical Outcomes Monitoring

On the path to better health, faster: effective management.

The faster you get the results, the sooner you can make life saving decisions. Our rapid CD4 test helps caregivers establish a baseline immune function and assess clinical outcome – while the patient is still there – to expedite treatment and management decisions. The m-PIMA™ Analyser brings HIV viral load testing to a wide range of decentralized settings.

Pima™ CD4 Cartridge

Absolute CD4 results in less than 20 minutes. Reduce patient loss to follow up with same day CD4 cell count results.

m-PIMA™ HIV-1/2 Viral Load

Point-of-care HIV Viral Load in less than 70 minutes. Designed to provide actionable results while the patient is still present.

HIV Co-Morbidities

Our industry-leading solutions help you screen for HIV-associated TB in minutes.

Studies show that HIV-positive people tend to be at higher risk of suffering from a range of non-AIDS co-morbidities.4 Tuberculosis (TB) is notoriously difficult to diagnose in HIV-infected people, with tools such sputum smear microscopy and chest radiography offering low sensitivity and specificity in this patient group. Helping you diagnose active TB in HIV-positive patients with result in minutes, the TB LAM Ag test offers the greatest sensitivity in the sickest patients.5

Alere Determine™ TB LAM Ag

Rapid rule-in for TB-HIV co-infection. Because it detects the TB LAM antigen, this tests enables you to diagnose both pulmonary and extra-pulmonary TB.


Decentralized healthcare management

What if you could give your patients confidence that they will be tested efficiently and accurately? The Sympheos™ System is a complete solution for managing point-of-care device health, monitoring stock and reviewing operator efficiency.

The Sympheos™ System

Better management through connectivity. The Sympheos™ System is an innovative online portal that gives you a real-time view of your healthcare programme.



Expand your knowledge

Fighting HIV in Africa

Our innovative diagnostic products are revolutionizing HIV chronic disease management at the point-of-care. Find out more about our approach.

Explore the Story

HIV Continuum of Care — Sierra Leone

Her Excellency Sia Nyama Koroma highlights the impact of donated Alere HIV/Syphilis Duo tests on pregnant women in Sierra Leone.


Based on your current location, the content on this page may not be relevant for your country.
Please click here to return to the homepage. Alternatively, click the X button to acknowledge and proceed.

contact us